Breaking News

Tweet TWEET

Venaxis to Present at 25th Annual ROTH Conference

              Venaxis to Present at 25th Annual ROTH Conference

PR Newswire

CASTLE ROCK, Colo., March 11, 2013

CASTLE ROCK, Colo., March 11, 2013 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its blood-based appendicitis test, APPY1, today announced that
it will present at the 25th Annual ROTH Conference, to be held March 17-20,
2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA.

Steve Lundy, President and CEO of Venaxis, will provide an overview of the
Company's business during his live presentation and will be available to
participate in one-on-one meetings with investors who are registered to attend
the conference.

  Event:  ROTH Conference
  Date:   Wednesday, March 20, 2013
  Time:   10:30 am (Pacific Time)
  Location: Track 3: Salon 2 - Blue; Ritz-Carlton Laguna Niguel; Dana Point,
  CA

The presentation will be webcast live. To access the webcast, please visit
the investor relations section of the Venaxis website at
http://ir.venaxis.com. The webcast replay will remain available for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its blood-based appendicitis test,
APPY1. The unique appendicitis test has projected high sensitivity and
negative predictive value and is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management. APPY1 is being developed initially for pediatric,
adolescent and young adult patients with abdominal pain, as this population is
at the highest risk for appendicitis and has the highest risk of long-term
health effects associated with CT imaging. For more information, visit
www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for APPY1 required for FDA submission, obtain FDA
clearance or approval, maintain CE Marking, cost effectively manufacture and
generate revenues from APPY1 at a profitable price point, execute agreements
required to successfully advance the company's objectives, retain the
management team to advance the products, overcome adverse changes in market
conditions and the regulatory environment, obtain and enforce intellectual
property rights, and realize value of intangible assets. Furthermore, Venaxis
does not intend (and is not obligated) to update publicly any forward-looking
statements. The contents of this press release should be considered in
conjunction with the risk factors contained in Venaxis' recent filings with
the SEC, including its Form 10-Q for the period ended September 30, 2012,
filed on November 7, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com

SOURCE Venaxis, Inc.

Website: http://www.venaxis.com